Linvoseltamab is a bispecific human IgG4 monoclonal antibody used for the treatment of multiple myeloma. By binding to both targets simultaneously, linvoseltamab redirects T cells toward myeloma cells, forming an immunological synapse that activates T-cell–mediated cytotoxicity.
- Mechanism
- Curator reviewed · 3 references
Multiple myeloma is characterized by the malignant proliferation of plasma cells that express B-cell maturation antigen (BCMA), a transmembrane receptor involved in B-cell differentiation and survival. T cells, through their CD3 receptor complex, can be harnessed to target tumor cells when appropriately engaged.
Linvoseltamab is a bispecific monoclonal antibody that binds to BCMA on myeloma cells and CD3 on T cells, bringing the two cell types into close proximity. This interaction forms an immunological synapse that activates T cells, leading to directed cytotoxicity against BCMA-expressing plasma cells. Upon engagement, linvoseltamab induces T-cell activation, proliferation, and the secretion of pro-inflammatory cytokines such as interferon-γ (IFN-γ), tumor necrosis factor (TNF), and interleukin-2 (IL-2), which further enhance anti-tumor activity and contribute to tumor cell lysis.
- Primary indication
- In the EU, linvoseltamab is indicated as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least 3 prior therapies, including a proteasome inhibitor, an immunomodulatory agent,...Curator reviewed · 4 structured indications
- Formula / weight
- 145600.0 Da
- First approval
- United States, 2025 · European Union, 2025
- Also known as
- human IgG4-based anti-CD3 x anti-BCMA bispecific monoclonal antibody that binds to CD3 and BCMA · Linvoseltamab-gcpt
- Code names
- REGN-458
Resolves to
What you can answer from here — as of March 06, 2026
Which drugs share a target with Linvoseltamab, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account